ERBB2 and breast cancer: The GeparSixto trial suggested that the pCR rate increased by 16.3% when carboplatin was added into the anthracycline-based NAC regimen for TNBC patients, whereas the improvement of pCR rate was not significant in HER2+ BC patients (59).